Hawthorn Pharmaceuticals cuts global deal with CoPlex
by MBJ Staff
Published: September 13,2011
MADISON — Hawthorn Pharmaceuticals Inc. has struck an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.
Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.
“In terms of the discovery’s uniqueness, it’s one of only few programs in the world demonstrating multiple protective effects against the predominant pathophysiologic pathways of Alzheimer’s disease,” said Rob Lewis, chief scientific officer at Hawthorn Pharmaceuticals.
“We are in the process of conducting the necessary preclinical studies in order to file an IND with the FDA,” said Max Draughn, Hawthorn Pharmaceuticals’ CEO.
To sign up for Mississippi Business Daily Updates, click here.
Top Posts & Pages
- Source: Bryant has offered Glenn McCullough MDA job
- College Board names Glenn Boyce as higher education chief
- TRANSITION AT THE MDA — Is Mississippi better off than it was 3 years ago?
- (WITH VIDEO) Funding secured for Capitol Art Lofts in downtown Jackson
- Deepwater Horizon Five Years Later — Restoring the Mississippi coast starts with a strong foundation
- PHIL HARDWICK: The third grade reading gate, book buddies and school principals
- Chancery Court’s interpretation of ‘public use’ will guide ruling on Westin money
- COMMERCIAL FINANCE 701: Loans disguised as government bonds (BOANs)
- THE SPIN CYCLE — Key results from Pew’s social media survey